Plasma Fractionation Market 2026

October 2025 | 220 pages | ID: P0EDD27F1198EN
DataM Intelligence

US$ 2,999.00 US$ 4,350.00 -31 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The Plasma Fractionation Market was valued at in and is anticipated to reach by , at a CAGR of 0.07 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Plasma Fractionation Market.

This report delivers a comprehensive overview of the Plasma Fractionation Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Plasma Fractionation Market. The Plasma Fractionation Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.

Plasma Fractionation Market Scope:

By Product
  • Albumin
  • Immunoglobulins
  • Coagulation Factor Concentrates
  • Protease Inhibitors
  • Others
By Application
  • Immunology
  • Neurology
  • Hemato-Oncology
  • Hematology
  • Critical Care
  • Pulmonology
  • Rheumatology
  • Others
By End-User
  • Clinical Research Laboratories
  • Hospitals & Clinics
  • Academic Institutes
  • Others
Key Players
  • CSL
  • Grifols
  • China Biologic Products
  • Shire (Takeda Pharmaceutical Company)
  • Octapharma Plasma, Inc.
  • Kedrion S.p.A
  • Sanquin
  • LFB SA
Major Highlights

This report delivers a comprehensive overview of the Plasma Fractionation Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Plasma Fractionation Market. The Plasma Fractionation Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
  • North America (U.S., Canada, Mexico)
  • Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
  • Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
  • South America (Colombia, Brazil, Argentina, Rest of South America)
  • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
  • Increase Your Customer Base by 3X using our Partner Identification tool
  • Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
  • Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
  • Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
  • Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
  • Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
  • White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
  • Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
  • Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
  • Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Market Snippet by Product
3.2. Market Snippet by Application
3.3. Market Snippet by End-User

4. MARKET DYNAMICS

4.1. Market Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Rising Prevalence of Respiratory Diseases
    4.1.1.2. Growing aging population globally
    4.1.1.3. Increasing demand of Immunoglobulins in various Therapeutic Areas
  4.1.2. Restraints
    4.1.2.1. Stringent Government Regulations
    4.1.2.2. High Cost and Limited Reimbursement
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Forces Analysis
5.2. Regulatory Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Unmet Needs

6. BY PRODUCT

6.1. Introduction
  6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
  6.1.2. Market Attractiveness Index, By Product Segment
6.2. Albumin*
  6.2.1. Introduction
  6.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
6.3. Immunoglobulins
  6.3.1. Subcutaneous Immunoglobulins
  6.3.2. Intravenous Immunoglobulins
  6.3.3. Others
6.4. Coagulation Factor Concentrates
  6.4.1. Von Willebrand Factor
  6.4.2. Factor IX
  6.4.3. Factor VIII
  6.4.4. Factor XIII
  6.4.5. Fibrinogen Concentrates
  6.4.6. Prothrombin Complex Concentrate
6.5. Protease Inhibitors
6.6. Others

7. BY APPLICATION

7.1. Introduction
  7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  7.1.2. Market Attractiveness Index, By Application Segment
7.2. Immunology*
  7.2.1. Introduction
  7.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
7.3. Neurology
7.4. Hemato-Oncology
7.5. Hematology
7.6. Critical Care
7.7. Pulmonology
7.8. Rheumatology
7.9. Others

8. BY END-USER

8.1. Introduction
  8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  8.1.2. Market Attractiveness Index, By End-User Segment
8.2. Clinical Research Laboratories*
  8.2.1. Introduction
  8.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
8.3. Hospitals & Clinics
8.4. Academic Institutes
8.5. Others

9. BY REGION

9.1. Introduction
  9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  9.1.2. Market Attractiveness Index, By Region
9.2. North America
  9.2.1. Introduction
  9.2.2. Key Region-Specific Dynamics
  9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    9.2.6.1. U.S.
    9.2.6.2. Canada
    9.2.6.3. Mexico
9.3. Europe
  9.3.1. Introduction
  9.3.2. Key Region-Specific Dynamics
  9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    9.3.6.1. Germany
    9.3.6.2. U.K.
    9.3.6.3. France
    9.3.6.4. Italy
    9.3.6.5. Spain
    9.3.6.6. Rest of Europe
9.4. South America
  9.4.1. Introduction
  9.4.2. Key Region-Specific Dynamics
  9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    9.4.6.1. Brazil
    9.4.6.2. Argentina
    9.4.6.3. Rest of South America
9.5. Asia Pacific
  9.5.1. Introduction
  9.5.2. Key Region-Specific Dynamics
  9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    9.5.6.1. China
    9.5.6.2. India
    9.5.6.3. Japan
    9.5.6.4. Australia
    9.5.6.5. Rest of Asia Pacific
9.6. Middle East and Africa
  9.6.1. Introduction
  9.6.2. Key Region-Specific Dynamics
  9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. COMPETITIVE LANDSCAPE

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

11.1. CSL*
  11.1.1. Company Overview
  11.1.2. Product Portfolio and Description
  11.1.3. Key Highlights
  11.1.4. Financial Overview
11.2. Grifols
11.3. China Biologic Products
11.4. Shire (Takeda Pharmaceutical Company)
11.5. Octapharma Plasma, Inc.
11.6. Kedrion S.p.A
11.7. Sanquin
11.8. LFB SA

12. PREMIUM INSIGHTS

13. DATAM INTELLIGENCE

13.1. Appendix
13.2. About Us and Services
13.3. Contact Us


More Publications